Thymosin Beta-4 for Corneal Healing: Eye Injury Research
Peptide Eye Research
6 of 10 Patients Healed
In the SEER-1 Phase III trial, 60% of neurotrophic keratitis patients treated with RGN-259 (thymosin beta-4 eye drops) achieved complete corneal healing in 4 weeks vs 12.5% on placebo.
Sosne et al., Int J Mol Sci, 2023
Sosne et al., Int J Mol Sci, 2023
View as imageThymosin beta-4 (TB4) is a 43-amino-acid peptide that appears naturally in human tear fluid, where it contributes to the maintenance of the corneal surface. When the cornea is injured, whether by infection, surgery, nerve damage, or chemical exposure, TB4 levels in the tear film change in ways that suggest the peptide plays an active role in the healing response. This observation led researchers to develop a synthetic version of TB4 as an ophthalmic solution, designated RGN-259, which has been tested through Phase III clinical trials for conditions where the cornea fails to heal on its own. Lacritin, another tear-derived peptide, is being studied for related ocular surface conditions, but TB4 has progressed further in clinical development for corneal wound healing.
Key Takeaways
- TB4 is naturally present in human tear fluid and promotes corneal epithelial cell migration, a critical step in wound closure
- RGN-259 (0.1% TB4 ophthalmic solution) achieved 60% complete corneal healing in neurotrophic keratitis patients at 4 weeks vs 12.5% on placebo in the SEER-1 Phase III trial
- The SEER-3 Phase III trial did not meet its primary endpoint, raising questions about reproducibility of clinical results
- TB4 acts as an adjunct to ciprofloxacin in bacterial keratitis, reducing inflammation by 80% and improving bacterial clearance in animal models (Carion et al., 2020)
- In diabetic corneal models, TB4 combined with vasoactive intestinal peptide (VIP) protected corneal epithelial cells from hyperglycemia-induced damage (Ebrahim et al., 2023)
- Wang et al. (2024) identified pro-resolving lipid mediators as key downstream effectors of TB4's anti-inflammatory action in corneal infection
Why the Cornea Is a Good Target for TB4
The cornea is the transparent front window of the eye. It is avascular (no blood vessels) and relies on tear fluid and aqueous humor for nutrition. Corneal wound healing depends almost entirely on epithelial cell migration: cells at the wound edge flatten, extend, and slide across the defect to close it. This is precisely the cellular behavior TB4 promotes.
TB4's primary biochemical function is sequestering G-actin, the monomeric form of actin that cells polymerize to build the cytoskeletal structures needed for movement. By regulating the pool of available actin monomers, TB4 modulates the cell's ability to extend lamellipodia and migrate across surfaces. In the cornea, this translates directly to faster epithelial wound closure.
Malinda et al. (1999) first demonstrated TB4's wound healing properties in a dermal model, showing accelerated repair with reduced inflammation.[1] The cornea offered a more defined system for studying these effects because corneal epithelial healing follows a well-characterized sequence of cell migration, proliferation, and differentiation, all measurable with standard ophthalmologic instruments.
TB4 also reduces corneal inflammation through pathways independent of its actin-sequestering function. The peptide downregulates pro-inflammatory cytokines including IL-1β, TNF-α, and matrix metalloproteinases (MMPs) that degrade corneal collagen and extracellular matrix. This dual mechanism, promoting epithelial migration while simultaneously reducing the inflammatory destruction of the tissue being repaired, makes TB4 particularly suited to corneal wound healing, where inflammation and repair must be carefully balanced.
There is also a practical advantage: the cornea is directly accessible. Unlike most organs, it can be treated with topical drops. This eliminates the systemic delivery challenges that complicate TB4 research in other organs, such as the cardiac applications where delivering the peptide to heart tissue requires either systemic injection or direct intracardiac administration.
RGN-259: From Lab to Clinical Trials
RegeneRx Biopharmaceuticals (later HLB Therapeutics) developed RGN-259, a sterile 0.1% thymosin beta-4 ophthalmic solution, as a topical treatment for corneal wound healing. The development program targeted two conditions: dry eye disease and neurotrophic keratitis.
Dry eye disease (DED) is a multifactorial condition affecting the tear film and ocular surface. Zhai et al. (2022) demonstrated that recombinant human TB4 modulated anti-inflammatory responses in a benzalkonium chloride-induced dry eye model, reducing levels of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6 while promoting corneal surface healing.[2]
In a Phase II randomized, placebo-controlled trial conducted using the Controlled Adverse Environment (CAE) model for dry eye, topical 0.1% TB4 significantly improved both signs and symptoms compared to placebo. No adverse effects attributable to the drug were observed.
Neurotrophic keratitis (NK) is a degenerative corneal condition caused by damage to the trigeminal nerve, which provides sensory innervation to the cornea. Without normal nerve signaling, the corneal epithelium loses its ability to maintain and repair itself, leading to persistent epithelial defects that can progress to ulceration, perforation, and vision loss. This condition is notoriously difficult to treat because the underlying nerve damage prevents normal healing responses.
The SEER Trial Program: Mixed Results
The clinical development of RGN-259 for neurotrophic keratitis proceeded through three Phase III trials designated SEER-1, SEER-2, and SEER-3.
SEER-1 produced encouraging results. In this randomized, placebo-controlled, double-masked trial, 6 of 10 patients (60%) in the RGN-259 group achieved complete corneal healing within 4 weeks, compared to 1 of 8 patients (12.5%) in the placebo group. RGN-259-treated patients also showed significant improvements in ocular discomfort, foreign body sensation, and dryness at multiple time points. These symptomatic improvements were not observed in the placebo group.
SEER-3, however, did not meet its primary endpoint. The trial failed to show a statistically significant difference in complete corneal healing at 4 weeks compared to placebo. This result raised questions about the reliability and reproducibility of the SEER-1 findings.
The discrepancy between SEER-1 and SEER-3 could reflect several factors. Neurotrophic keratitis is a heterogeneous condition: the severity of nerve damage, the underlying cause (viral infection, surgery, diabetes, stroke), and the duration of the disease all vary between patients. Small Phase III trials in rare diseases are vulnerable to patient selection effects, where a few outlier responders can dramatically shift results. The SEER-1 sample size (18 patients total) was too small to draw definitive conclusions, making the failure of the larger SEER-3 trial a significant setback.
The challenge of neurotrophic keratitis trials extends beyond TB4. The condition is rare (affecting an estimated 5 in 10,000 people), heterogeneous in etiology and severity, and has no widely accepted standardized clinical endpoint. Cenegermin (Oxervate), the only FDA-approved treatment for neurotrophic keratitis, faced similar challenges during its development. The existence of an approved competitor also changes the regulatory calculus for any new entry, since head-to-head comparisons rather than placebo-controlled trials may now be required.
As of 2026, RGN-259 has not received FDA approval.
TB4 in Bacterial Keratitis: Adjunct to Antibiotics
While the clinical trial program for neurotrophic keratitis has stalled, research into TB4 as an adjunct treatment for bacterial corneal infections has produced consistent preclinical results.
Bacterial keratitis, particularly that caused by Pseudomonas aeruginosa, involves rapid corneal destruction from both the bacterial infection itself and the host inflammatory response. Standard treatment with fluoroquinolone antibiotics like ciprofloxacin effectively kills bacteria but does not address the inflammatory damage, which continues to destroy corneal tissue even after the infection is cleared.
Carion et al. (2020) demonstrated that TB4 combined with ciprofloxacin produced both antimicrobial effects and reduced inflammatory damage in a Pseudomonas keratitis model.[3] The combination therapy reduced corneal inflammatory infiltrate by approximately 80% compared to ciprofloxacin alone while maintaining antibacterial efficacy.
Wang et al. (2021) investigated the mechanism behind these effects and found that adjunctive TB4 treatment modulated polymorphonuclear neutrophil (PMN) function during Pseudomonas corneal infection.[4] The peptide shifted PMN behavior from tissue-destructive to tissue-protective patterns without compromising bacterial killing. A companion study by the same group documented similar modulatory effects on macrophage function.[5]
Sosne et al. (2023) reviewed the accumulated evidence for TB4 in bacterial keratitis and proposed it as a "potential novel adjunct treatment" based on its combined anti-inflammatory, antimicrobial, and pro-healing properties.[6] The key advantage of TB4 over corticosteroids (the standard anti-inflammatory approach in keratitis) is that TB4 does not suppress immunity or impair wound healing, both serious risks with steroid use in infected corneas.
Wang et al. (2024) identified the molecular mechanism: TB4 activates pro-resolving lipid mediator pathways, including lipoxins and resolvins, that shift the inflammatory response from tissue destruction toward active resolution and repair.[7] This finding provides a specific mechanistic target for future drug development.
Diabetic Corneal Disease
Diabetes damages corneal nerves and impairs epithelial healing through mechanisms similar to neurotrophic keratitis. Diabetic patients frequently develop corneal complications including persistent epithelial defects, recurrent erosions, and increased susceptibility to infection. Current treatments are limited.
Ebrahim et al. (2023) investigated a novel combination therapy of TB4 and vasoactive intestinal peptide (VIP) for hyperglycemia-induced corneal epithelial damage.[8] The combination protected human corneal epithelial cells from high-glucose-induced changes in cell viability and morphology. The combination approach, using two peptides with complementary mechanisms (TB4 for cell migration and wound healing, VIP for neuroprotection), suggests that diabetic corneal disease may require multi-target therapy.
Diabetic corneal complications affect an estimated 47% to 64% of diabetic patients. The damage is progressive: hyperglycemia injures corneal nerves, leading to reduced sensation, impaired epithelial cell turnover, and increased vulnerability to infection and erosion. Current treatments are limited to lubricating drops, bandage contact lenses, and autologous serum eye drops, none of which address the underlying pathology. TB4's ability to both promote epithelial migration and modulate the inflammatory response to nerve damage makes it a mechanistically appropriate candidate, though clinical evidence in diabetic patients remains preclinical.
The Broader Context: TB4 as a Tissue Repair Peptide
TB4's corneal effects are a specific instance of a broader tissue repair mechanism. The peptide promotes cell migration and anti-inflammatory resolution across multiple tissue types, from skin wounds to cardiac tissue. The cornea's advantages as a therapeutic target, topical accessibility, defined wound healing biology, and measurable clinical endpoints, explain why ophthalmic applications have progressed further in clinical development than other TB4 indications.
The SEER trial results illustrate a common challenge in peptide therapeutics: promising preclinical and early clinical data does not always translate into consistent Phase III results. The antimicrobial peptide approach to corneal infections represents a parallel line of ocular peptide research using different peptide classes.
TB4 corneal research continues along two tracks. The bacterial keratitis data, with its consistent preclinical results and clear mechanistic understanding through pro-resolving lipid mediator pathways, may offer a more reliable path to clinical development than the neurotrophic keratitis indication where trial results have been inconsistent. The diabetic corneal disease application, while still preclinical, addresses a large unmet need with limited existing treatments.
The fundamental biology is sound: TB4 promotes the specific cellular behaviors needed for corneal repair (epithelial migration, anti-inflammatory resolution) while avoiding the immunosuppression risks of corticosteroids. The challenge is not mechanism but clinical translation, designing trials in heterogeneous patient populations with endpoints that reliably capture meaningful therapeutic benefit.
The Bottom Line
TB4 promotes corneal healing through epithelial cell migration and anti-inflammatory pathway activation. RGN-259 (0.1% TB4 eye drops) showed 60% complete healing in neurotrophic keratitis patients in the SEER-1 Phase III trial, but the larger SEER-3 trial failed to meet its primary endpoint. The compound has not received FDA approval. Preclinical research in bacterial keratitis has been more consistent, with TB4 as an antibiotic adjunct reducing corneal inflammation by approximately 80% while preserving bacterial killing. The pro-resolving lipid mediator pathway has been identified as a key mechanism. Diabetic corneal disease represents an emerging application.